Editas Medicine (EDIT) Reports Q4 Loss of $1.00/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Editas Medicine Announces Fourth Quarter and Full Year 2020 Results and Update
February 25, 2021 7:00 AM ESTStrengthened Leadership by Appointing James (Jim) C. Mullen as President and Chief Executive Officer, and Lisa A. Michaels, M.D., as Chief Medical Officer
Appointed Meeta Chatterjee, Ph.D., to Board of Directors
Initiated dosing of adult mid-dose cohort of BRILLIANCE trial of EDIT-101 for LCA10
Initiated Phase 1/2 RUBY trial for EDIT-301 for sickle cell disease
Ended 2020 with strong cash position of $512 million, and raised additional $250 million in early 2021
CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Editas Medicine,... More
